A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

By sjmartinez • October 22, 2022

Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, Donovan JA, Alcorn JM, Chao DC, Asghar A, Morgan TR; Southern California Alcoholic Hepatitis (SCAH) Consortium. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis. EClinicalMedicine. 2022 Oct 12;54:101689. doi: 10.1016/j.eclinm.2022.101689. PMID: 36267499; PMCID: PMC9576807.

Tags: ACLF, acute kidney injury, acute on chronic liver failure, AH, AKI, alcohol-related hepatitis, Alcoholic hepatitis, common terminology criteria for adverse events, CTCAE, data safety monitoring board, DF, discriminant function, DSMB, FDA, follow-up, food and drug administration, FU, GCSF, General Internal Medicine, granulocyte colony stimulating factor, Harbor UCLA, hepatorenal syndrome, HIV, HRS, human immunodeficiency virus, INR, international normalized ratio, national institute on alcohol abuse and alcoholism, NIAAA, Pegfilgrastim, Phase II, Publications, Randomized clinical trial, SD, SOC, standard deviation, standard of care, WBC, white blood cell count

William J. Carroll, MD, FACP Appointed Section Chief of Palliative Care and Extensivist Medicine

The UCLA Department of Medicine (DoM) is pleased to announce the appointment of William J. Carroll, MD, FACPas section chief of the UCLA DoM Palliative Care[...]

Joshua N. Khalili, MD Appointed to DoM Chief Wellness Officer

The UCLA Department of Medicine has appointed Joshua N. Khalili, MD to chief wellness officer (CWO) effective April 1. The appointment builds on Dr. Khalili’s outstanding work[...]

Sun M. Yoo, MD, MPH to Depart DoM to Pursue New Leadership Opportunity

The UCLA Department of Medicine (DoM) announces that Sun M. Yoo, MD, MPH, will be departing UCLA Health to assume the role of a founding chief[...]